Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.

4 Aug 2011

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

4 Aug 2011

Researchers discover new tick-borne bacterium that causes ehrlichiosis in Wis., Minn.

A new tick-borne bacterium infecting humans with ehrlichiosis has been discovered in Wisconsin and Minnesota. It was identified as a new strain of bacteria through DNA testing conducted at Mayo Clinic.

4 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

SDIX adds nine new polyclonal antibodies to IVD reagents portfolio

SDIX, a leading provider of In Vitro Diagnostic (IVD) reagents, announced the addition of nine new polyclonal antibodies to its product line for the IVD market while exhibiting at AACC last week.

3 Aug 2011

Antibody discovery leads researchers one step closer to universal influenza A vaccine

"The first human antibody that can knock out all influenza A viruses has been shown effective in lab mice, an exciting step forward in the hunt for a universal vaccine, researchers said Friday," Agence France-Presse reports.

2 Aug 2011

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

1 Aug 2011

Universal flu vaccine based on “super antibody” coming soon

Researchers have finally found the first antibody which can fight all types of the influenza A virus. The results of the experiments on flu-infected mice, published in Science Express, showed the antibody could be used as an “emergency treatment” for flu as well.

31 Jul 2011

Caltech researchers find simple engineering technique to ward off HIV

If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.

30 Jul 2011

UK MRC, Humabs discover first neutralizing antibody that targets all influenza A subtypes

A paper published today in the scientific research journal Science, describes a novel, proprietary monoclonal antibody (FI6) discovered in a collaboration between Humabs BioMed SA, the Institute for Research in Biomedicine and the UK Medical Research Council.

29 Jul 2011

FDA issues Refusal to File letter for Eisai's perampanel NDA to treat partial-onset seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy which was submitted in May 2011.

29 Jul 2011

Sorrento receives NIAID Phase I STTR grant to develop vaccines against C. difficile infection

Sorrento Therapeutics, Inc. announced today that it has received a Phase I Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

29 Jul 2011

Universal flu vaccine with super antibodies in near future

Researchers are close to developing a “super antibody” against flu that could be used as a universal treatment and pave the way for the development of a universal vaccine against the disease that affects billions of people every year.

29 Jul 2011

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. presented data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia.

28 Jul 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011

Epitomics launches 23 novel cancer-related antibodies

Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research.

27 Jul 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

Follow-up dose recommended to defend children against pandemic virus outbreaks

Researchers from Australia determined that pediatric liver transplant patients who received a single-dose of the H1N1 vaccine were not adequately protected against the virus compared to healthy children.

27 Jul 2011